Circulating tumour cells (CTCs) are shed into the bloodstream from primary and metastatic solid tumours and are seen as important emerging biomarkers of cancer ([@bib18]; [@bib4]). Sensitive and specific detection of CTCs is crucial to enable their predictive and prognostic use. There is evidence to suggest current methods do not detect all CTCs present in a blood sample and may miss CTCs with low expression of commonly used epithelial markers such as EpCAM or the cytokeratin family ([@bib12]; [@bib13]). Further evidence suggests that CTCs associated with ER-negative breast cancers that express a putative tumour stem cell phenotype (often associated with aggressive disease), are not detected ([@bib17]). As it is hoped that CTCs will provide information for personalised therapy, it is important to be able to detect the full heterogeneity present in a CTC population by detecting a number of tumour markers. This is particularly important in early stage cancer where CTCs are very rare and their characterisation could enable the potential eradication of micrometastases by the use of specific therapies. Single-cell detection and characterisation is limited owing to the technical difficulties of isolating adequate numbers of cells from the blood as well as the problems (both cost and optimisation time) in multiplexing antibodies against multiple tumour markers. Antibody staining is also prone to low specificity and user subjectivity when interpreting the staining ([@bib6]).

The use of quantitative reverse transcription real-time PCR (qRT-PCR) for detecting multiple tumour marker mRNAs from blood is a highly sensitive method. One drawback is the detection of illegitimate transcripts present in blood cells, and it also does not account for tumour cell heterogeneity. The use of a method to detect tumour marker mRNAs in single CTCs *in situ* is therefore attractive. However, the use of RNA *in situ* hybridisation (ISH) in CTCs has drawn little attention owing to limited sensitivity and specificity of conventional RNA ISH methods. Recently, an ultrasensitive and specific multiplex RNA ISH technology, RNAscope, was developed, which is capable of single RNA molecule detection ([@bib22]; [@bib24]). This technology can detect multiple transcripts simultaneously in two ways: the target probes for different genes can have the same recognition sequence for the signal amplification system, thus generating a 'pooled\' signal; alternatively, multiple independent signal amplification systems can be used to simultaneously detect multiple target RNA species each as a distinct signal. This unique feature of the technology makes it well suited for CTC identification and characterisation. Here, we describe the development and characterisation of CTCscope using a panel of epithelial and tumour mRNA markers and demonstrate its use in the detection of single viable CTCs from metastatic breast cancer patients and its correlation with progression-free survival.

Materials and methods
=====================

Study design
------------

Breast cancer patients with metastatic disease were recruited prospectively and sequentially from Charing Cross Hospital, London. The study had been approved by the Local Ethics Committee. All patients provided written, informed consent. The primary tumour characteristics of these patients are detailed in [Table 1](#tbl1){ref-type="table"}. Patients were included if they had histologically confirmed evidence of metastatic breast cancer. Clinical examination and either Computed Tomography or Magnetic Resonance Imaging scans were performed at the start of the study (time of blood sampling) and then every 6 weeks following sampling. Disease progression status was assessed using the RECIST (Response Evaluation Criteria for Solid Tumours) ([@bib21]; [@bib5]).

Control blood samples from healthy donors were collected at the Stanford Blood Center (Palo Alto, CA, USA).

Statistical analysis
--------------------

Progression-free survival (PFS) was the interval from the date of blood sampling to the date of clinical progression or death due to any cause. PFS differences according to CTC status (presence or absence) and CA15-3 levels (using median as the cutoff) were computed using the Kaplan--Meier method and compared by log-rank test. Univariate Cox proportional hazard regression analysis was used to assess prognostic performance of CTC detection and CA15-3 levels. Concordance of CTC detection (present or absent) between CTCscope and CellSearch was assessed by Fisher\'s exact test. The correlation between CA15-3 levels and CTC numbers was examined by Spearman rank correlation. All calculations were performed in the R statistical environment. All significance tests were two-sided, and a *P*\<0.05 was considered statistically significant.

The Cellsearch system
---------------------

Blood samples were collected in CellSave preservative tubes (Veridex LLC, Raritan, NJ, USA) and processed within 72 h of collection. The CellSearch system ([@bib15]) uses magnetic iron particles conjugated to antibodies against the epithelial cell adhesion molecule (EpCAM) to immunomagnetically enrich epithelial cells. The cells were labelled with the fluorescent nucleic acid dye 4′,6-diamidino-2-phenylindole (DAPI); a mixture of two phycoerythrin-conjugated antibodies that bind to cytokeratins 8, 18 and 19 and a allophycocyanin-conjugated CD45 antibody (to distinguish CTCs from leukocytes). A control consisting of SK-BR-3 cells was also used in each run to ensure the efficiency and specificity of detecting a low and high population of CTCs (Veridex LLC). Briefly, each 7.5 ml sample of blood was mixed with 6.5 ml of buffer and centrifuged at 800 **g** for 10 min, and then placed in the Autoprep system. The cells were then aspirated into the MagNest cell presentation device (Veridex LLC). This device is made up of a chamber and two magnets that hold the immunomagnetically labelled cells to the surface of a cartridge for analysis using the CellTracks Analyser.

Measurement of serum CA15-3
---------------------------

CA15-3 was measured in serum using the Abbott Architect Ca 15-3 kit. This uses both 115D8 and DF3 monoclonal antibodies; the assay has a sensitivity of \<0.5 U ml^−1^ and has been extensively described in the literature ([@bib7]).

Method for spiking cancer cells in blood
----------------------------------------

To spike rare numbers (\<100) of tumour cells in blood, a suitable concentration of cultured cancer cells (e.g. MDA-MB-468) were resuspended (1 000 to 100 000 cells ml^−1^) in DMEM-supplemented media. One *μ*l of cell suspension was transferred to the corner of a glass coverslip. The cells were then enumerated using a tally counter under × 10 magnification on a bright field microscope with the entire 1 *μ*l drop in the field of view. The entire drop of cell suspension was then transferred into 5 ml of blood of healthy donor in a blood collection tube by flushing four times with 50 *μ*l 1 × phosphate-buffered saline (PBS). All the residual PBS on the slide was also transferred to the tube to minimise cell loss. The blood tube was then inverted 5--10 times with the lid on.

Peripheral blood mononuclear cell (PBMC) preparation for CTCscope
-----------------------------------------------------------------

Peripheral blood (7.5 ml) was drawn into a vacutainer with EDTA and processed within 6 h. Peripheral blood mononuclear cells were then prepared via Ficoll-gradient using Accuspin system-histopaque-1077 tubes (Sigma-Aldrich, St Louis, MO, USA) according to the manufacturer\'s manual, and fixed in 10% buffered formaldehyde solution at 37 °C for 40 min with rotation. The cells were then washed and stored in 700 *μ*l 70% ethanol at room temperature. Metastatic patient blood samples were processed according to the same protocol and stored for up to a month before CTCscope analysis.

CTCscope assay
--------------

*In situ* hybridisation probes were designed to target *CK5, CK6, CK8, CK14, CK17, CK18, CK19, CK20, EpCAM, MUC1, VIM, TWIST, CDH2 (N-Cadherin)*, *FN1* (fibronectin) and *CD45* mRNAs, respectively, using a computer algorithm described earlier ([@bib3]) (see [Supplemental Table 2](#sup1){ref-type="supplementary-material"} for target regions). Each oligo probe has an average length of 25 nucleotides in the target recognition region and is designed to have a Tm within a defined range so that all the target probes will hybridise optimally under the assay conditions. For CTCscope staining, formaldehyde-fixed cells were spun onto SuperFrost Plus glass slides using a Hettich cyto-centrifuge and air dried. Typically, two-thirds of the preparation (∼5 ml blood) was cytospun onto slides for CTCscope analysis. The samples were then processed with the RNAscope assay described previously ([@bib24]). Briefly, the cells were treated with protease followed by incubation with the target probes at 40 °C for 3 h. The signal is amplified by a series of nucleic acid hybridisation events that result in accumulation of a large number of oligonucleotide probes conjugated with Alexa fluorescent dyes ([@bib24]). Different target probes can be pooled and labelled with the same fluorescent colour, or with different colours in a multiplex assay. Nuclei were stained with 4\',6-diamidino-2-phenylindole, dihydrochloride (DAPI).

Circulating tumour cell enumeration and imaging
-----------------------------------------------

Circulating tumour cells were enumerated manually under × 20 magnification on a Zeiss (New York, NY, USA) Axioplan M1 microscope, using the Alexa488 channel (Life Technologies, Carlsbad, CA, USA) (panCTC staining). A sample was qualified for CTC scoring if the majority of PBMCs stained positively with CD45 (Alexa546 channel, Life Technologies), indicating acceptable RNA integrity. A CTC was identified by strong positive panCTC mRNA staining, positive nuclear staining (DAPI channel), and no CD45 mRNA signal. Circulating tumour cell images were acquired with the Nuance Multispectral Imaging System (CRI, Cambridge, MA, USA) using a combination of long-pass filter sets: DAPI (425 nm/475 nm), Alexa488 (470 nm/515 nm), and Alexa546 (535 nm/590 nm). Overlapping signals from different fluorophores were separated by comparing composite signals to a reference spectral library generated with single colour stained samples.

CTCscope/antibody double staining
---------------------------------

MDA-MB-468 cells were trypsinised, fixed, and stained according to the CTCscope protocol using pan-CK probes (CK8, CK18, and CK19) labelled with Alexa546. The samples were then blocked in 1 × PBS with 1% BSA for 30 min at room temperature, and then incubated with M30 antibody (Roche, Indianapolis, IN, USA, cat. no. 12140322001) or Mouse anti-Cytokeratin antibody (Clone AE1/AE3, Invitrogen Technologies, Carlsbad, CA, USA, cat. no. 08-4132) for 1 h at room temperature. The samples were washed and then incubated with FITC-conjugated goat anti-mouse antibody (Millipore, Billerica, MA, USA, cat no. 12-506) for 30 min at room temperature. Cell nuclei were stained with DAPI. Images were acquired with the Nuance Multispectral Imaging System (CRI) using the same filter set used for CTC analysis.

Results
=======

The CTCscope assay
------------------

The workflow of the CTCscope assay is shown in [Figure 1A](#fig1){ref-type="fig"}. CTCscope uses PBMC fractions obtained from whole blood using a Ficoll-gradient collection tube. This step provides limited enrichment by removing red blood cells and platelets but does not separate CTCs from white blood cells. Unlike other CTC detection methods, further enrichment from white blood cells is not required for this method owing to the highly sensitive and specific detection system employed. To evaluate the capability of CTCscope in the detection and characterisation of CTCs, probe sets against mRNAs encoding cytokeratin 8, 18, and 19 were combined (pan-CK) to detect epithelial cells. Another probe set was used on a separate colour to detect *EGFR* mRNA expression in CTCs. To determine whether rare cancer cells could be detected by CTCscope, cultured breast cancer cell lines (MCF7, SK-BR-3 and MDA-MB-468) were spiked into whole blood obtained from healthy individuals at approximately 50 cells per 10 ml of blood. Peripheral blood mononuclear cells were collected and stained according to the CTCscope protocol. Spiked-in cells of all three cell lines could be identified by strong pan-CK staining, whereas the surrounding PBMCs showed minimal fluorescent signals ([Figure 1B](#fig1){ref-type="fig"}). In addition, MCF7, SK-BR-3, and MDA-MB-468 cells showed different *EGFR* mRNA expression levels, with MDA-MB-468 having the highest level of *EGFR* transcripts, SK-BR-3 at a medium level, and the majority of MCF7 cells having no *EGFR* mRNA expression ([Figure 1B](#fig1){ref-type="fig"}). These results are consistent with the known EGFR protein expression status in these cell lines ([@bib8]; [@bib11]; [@bib25]) demonstrating CTCscope\'s molecular profiling capability.

Given that cancer cells with different origins or at different progression stages have varied expression levels of cytokeratins and other epithelial cell markers, we incorporated additional target probes into our CTC detection system to further enhance its sensitivity. The expanded CTC panel (panCTC) included traditional epithelial cell markers (cytokeratins 8, 14, 17, 18, 19, and 20, EpCAM, and MUC-1) and three genes expressed in tumour cells that have undergone EMT) ([@bib26]; [@bib27]). All these markers were independently tested by staining PBMCs purified from blood with spiked-in cells of MDA-MB-468 and MRC-5 (a lung fibroblast cell line expressing Twist, N-Cadherin, and fibronectin), and they were found to be specific to the spiked-in cells and were not detectable in background PBMCs ([Supplementary Figure 1A and B](#sup1){ref-type="supplementary-material"}). Several other epithelial and EMT markers, including cytokeratin 5, 6, and vimentin, were also tested, but they were excluded from the CTC detection panel owing to their expression in blood cells ([Supplementary Figure 1C](#sup1){ref-type="supplementary-material"}). A negative selection marker (CD45) was also developed to ensure that no leukocytes were counted as CTCs. CD45 also served as an RNA quality indicator, and only those samples with *CD45* RNA staining in PBMCs were qualified for subsequent CTC screening. A CTC was identified as a nucleated (DAPI-positive) cell with positive staining of CTC markers but no staining for *CD45*.

To determine whether the expanded panel of CTC markers (panCTC) could lead to higher detection sensitivity compared with pan-CK markers (CK8, CK18, and CK19), MDA-MB-468 cells were hybridised with probes to detect CK19, pan-CK, and panCTC markers, respectively. As expected, an increase in fluorescent signal was observed when the number of combined probes increased ([Supplementary Figure 1D](#sup1){ref-type="supplementary-material"}). We next confirmed that the increased sensitivity of the panCTC panel did not result in a decrease in specificity: blood samples from 13 healthy volunteers were analysed by CTCscope, and no panCTC-positive cells were identified.

To assess the recovery rate and assay linearity of CTCscope, a breast cancer cell line (MDA-MB-468) was spiked at different concentrations (1--92 cells per 5 ml) into blood from healthy donors. The PBMCs were collected and CTCscope performed. The average recovery rate was 71%±12% (*n*=17) ([Figure 1C](#fig1){ref-type="fig"}).

Given that RNA degrades quickly upon apoptosis, we hypothesised that CTCscope should only detect live CTCs but not dead or apoptotic cells (at the time of fixation). To test this, we performed a CTCscope assay on MDA-MB-468 cells, followed by immunostaining with M30, an epithelial cell apoptosis marker antibody ([@bib10]) or pan-CK antibody. A population of naturally occurring apoptotic cells could be identified by their positive M30 staining; consistent with our hypothesis. These M30-positive apoptotic cells had undetectable pan-CK RNA expression ([Figure 2A](#fig2){ref-type="fig"}, white arrows). Note that all cells stained positively for either pan-CK RNA or M30 but not both, suggesting that an apoptotic CTC cannot be stained by RNAscope. In contrast, the pan-CK antibody stained all cells including those with low or no pan-CK RNA staining ([Figure 2B](#fig2){ref-type="fig"}), suggesting that pan-CK protein staining could not distinguish live cells from cells undergoing apoptosis.

CTCscope analysis of blood samples from breast cancer patients
--------------------------------------------------------------

We next wanted to demonstrate whether the CTCscope assay could be used to detect CTCs in patients\' blood. In all, 45 unselected breast cancer patients with metastatic breast cancer were recruited over a 5-month period from a single institution. Of the 45 patients, 40 (89%) received cytotoxic, hormonal, biological or bisphosphonate treatments and 5 (11%) received no treatment following blood sampling. In all, 23 patients (51%) had progressive disease, 15 (33%) had stable disease, and 7 (16%) had a partial response according to RECIST criteria ([@bib21]; [@bib5]) during the follow-up period of a median of 16 weeks. All patients had duplicated blood samples taken for direct comparison between the CellSearch system and CTCscope (see [Supplemental Table 1](#sup1){ref-type="supplementary-material"} for the number of CTCs detected for each patient). Approximately 5 ml of blood was analysed by CTCscope, whereas 7.5 ml was processed by CellSearch.

After staining by CTCscope, candidate CTCs were identified by screening at low magnification ([Figure 2C](#fig2){ref-type="fig"}) for positive panCTC marker staining. High magnification images were then taken to confirm the identification of CTCs by the absence of CD45 staining. In general, the CTCs identified in the patients could be categorised according to cell size. In some patients, CTCs had a similar or slightly larger size than PMBCs ([Figure 2D](#fig2){ref-type="fig"}), whereas in other patients, the CTCs were significantly larger ([Figure 2E](#fig2){ref-type="fig"}). It is worth noting that we also observed some cells with apparent tumour cell morphology (e.g. large nuclei) or tumour cell clusters which showed no panCTC marker staining ([Figure 2F](#fig2){ref-type="fig"}). It is possible that these CTCs had undergone apoptosis and were therefore not detectable by CTCscope. CTCscope and CellSearch detected at least one CTC in similar proportions of patients: CTCscope detected CTCs in 21 out of 45 patients (47%) and the CellSearch system detected CTCs in 23 out of 45 patients (51%). The two methods had concordant results for 31 of the 45 patients (69% *P*=0.017, Fisher\'s exact test); 15 patients (33%) were positive for CTCs by both methods and 16 patients (36%) were negative for CTCs by both methods. A proportion of patients had CTCs detected by only one method, 8 (18%) by the CellSearch system and 6 (13%) by CTCscope. A total of 29 out of 45 (64%) patients showed the presence of CTCs by one or both methods. The CellSearch system detected far more cells than CTCscope with a mean of 19.53 compared with 1.56 and a median of 1 compared with 0 CTCs per 7.5 ml of blood ([Table 2](#tbl2){ref-type="table"}).

Detection of CTCs by CTCscope predicts PFS
------------------------------------------

The CTC status for each patient was defined as either positive (at least one CTC detected) or negative (no CTC detected). Progression-free survival differed significantly according to CTC status by either CTCscope (log-rank *P*=0.014) or CellSearch (*P*=0.006) with positive CTC status associated with shorter PFS ([Figure 3](#fig3){ref-type="fig"}). CellSearch results were also significantly associated with PFS when the established cutoff of 5 CTCs for CellSearch ([@bib4]) was used (*P*=0.013; [Figure 3](#fig3){ref-type="fig"}). Consistent with being a prognostic factor in breast cancer, CA15-3 levels also significantly predicted PFS (*P*=0.004; [Figure 3](#fig3){ref-type="fig"}).

We also performed univariate Cox regression to further evaluate the association of CTC status with PFS ([Table 3](#tbl3){ref-type="table"}). Circulating tumour cell status by CellSearch had a slightly increased association with PFS (HR 2.50, 95% CI 1.27--4.90, *P*=0.008) than that by CTCscope (HR 2.26, 95% CI 1.18--4.35, *P*=0.014). In addition, serum CA 15-3 levels had a stronger correlation with CTC numbers by CellSearch (Spearman rho=0.52, *P*=0.0003) than by CTCscope (rho=0.24, *P*=0.09) ([Table 3](#tbl3){ref-type="table"}).

Discussion
==========

Circulating tumour cells (CTCs) are extremely rare in the blood at around CTC per billion blood cells, even in metastatic cancer patients. As a result, their detection and characterisation remains a significant technical challenge. Here, we have described a novel RNA ISH assay, CTCscope, for both the detection and molecular analysis of CTCs. By using cell line models, we demonstrated that CTCscope is highly sensitive and specific for CTC detection in blood samples without special enrichment. This is a significant feature of CTCscope because current enrichment methods, such as EpCAM-based immuno-enrichment and cell size-based filtration, do not detect all CTCs due to the significant heterogeneity in antigen expression and cell size. The ability to detect CTCs expressing low levels of classical epithelial markers, such as CKs and EpCAM, was enhanced in CTCscope in two ways. Firstly, the panCTC gene panel included a cocktail of eight epithelial markers, increasing the sensitivity of detecting epithelial marker expression. Secondly, the panCTC panel included three markers of EMT. Evidence of co-expression of epithelial and mesenchymal markers in CTCs has been shown ([@bib1]), however CTCs with EMT characteristics can have low or undetectable levels of CK/EpCAM expression and are thus not effectively detected by methods relying on epithelial markers alone ([@bib9]; [@bib14]). These cells have been attracting increasing attention in CTC research owing to their ability to invade and seed metastasis on one hand and to evade chemotherapy on the other ([@bib2]). In addition, using cell line models, we showed that unlike protein marker-based detection methods, CTCscope only detected viable CTCs with intact RNA, excluding dead cells from enumeration. This is desirable because only the viable CTCs are likely to have metastatic potential. This property of CTCscope may be particularly useful in monitoring therapeutic response, where the number of surviving CTCs may be more indicative of disease progression and of emerging resistance to therapy than that of the total CTC population.

We also demonstrated efficacy of CTCscope in metastatic breast cancer patients by conducting a head-to-head comparison with CellSearch. This study showed CTCscope detected CTCs in 47% of patients compared with 51% of patient with CTCs by the CellSearch system using 5 ml *vs* 7.5 ml of blood. The concordance was high with 31 out of 45 (69%) patients with results that concurred. The CellSearch system however, detected many more CTCs than CTCscope in most patients, with a mean of 19.53 compared with 1.56 and a median of 1 compared with 0, respectively. The spiking experiments showed a 71% recovery rate, however, so it should therefore theoretically detect similar numbers of CTCs as the CellSearch system. This discrepancy may be due to loss of CTCs during Ficoll-gradient fractionation or damage to CTCs in patient blood by the pre-processing method used in CTCscope, whereas breast cancer cell lines may be more robust and homogeneous. Alternatively, a substantial proportion of CTCs in breast cancer patients may be dead, dying or in a quiescent or dormant state, and are thus 'invisible\' to CTCscope, which requires presence of intact RNA. Evidence for this includes heterogeneity of the proliferation marker Ki-67 in CTCs, and also the finding of a short half-life of CTCs from prostate cancer patients suggesting a dying phenotype in the blood ([@bib19]). The presence of an apoptotic marker has been found in CTCs, which also suggests a dying phenotype and may explain the discrepancy between the number of CTCs detected by CTCscope and by the CellSearch system ([@bib16]). Therefore, although CellSearch detects more CTCs, CTCscope detects clinically important viable, non-apoptotic cells, with intact mRNA.

We investigated whether CTC detection was prognostic of patient outcome in metastatic breast cancer patients. As expected, CTCs detected by CellSearch-predicted shorter PFS. Despite the much lower number of CTCs detected by CTCscope, the presence of at least one CTC also correlated significantly with shorter PFS in metastatic breast cancer patients. This highlights the functional importance of the cells detected with this technology. In addition, CTCs detected by CellSearch positively correlated with the serum tumour marker CA 15-3 levels but CTCs detected by CTCscope did not. This difference in correlation to CA15-3 between CTCscope and CellSearch may be due to their different ability to detect apoptotic/dead cells. CA15-3, derived from the MUC1 protein, is likely to be shed from both viable and apoptotic/dead cells (perhaps even more from the latter). This corresponds well to the inability of CellSearch to discriminate apoptotic/dead cells from viable cells. In contrast, the number of CTCs detected by CTCscope did not include apoptotic/dead cells and were thus less correlated with CA15-3 levels.

Multiplex reverse-transcription real-time PCR (qRT-PCR) is another approach to detect and characterise CTCs at the mRNA level ([@bib23]; [@bib20]). In this approach, partially or highly enriched CTCs are obtained for RNA extraction and analysis. Although qRT-PCR has high analytical sensitivity and specificity and is also quantitative, it has important limitations in CTC analysis. Firstly, it does not allow direct enumeration of CTCs. Secondly, the measured expression levels of tumour markers represent the 'averages\' of a heterogeneous population of cells analysed. This lack of cellular resolution masks the heterogeneous nature of CTCs and leads to 'dilution\' by non-CTCs. Thirdly, basal levels of expression of epithelial markers in blood cells can lead to false positive results. CTCscope avoids these issues by enabling single-cell level analysis. Because of the single molecule sensitivity of the underlying RNAscope technology, tumour marker expression levels can be quantified by counting the puncate fluorescent dots, which can be automated by image analysis algorithms.

Several aspects of CTCscope may be further improved. Firstly, using a more effective and gentle approach in pre-processing of blood samples to prevent damage to CTCs may further increase recovery of greater numbers of intact CTCs. Secondly, the search for relevant subpopulations of CTCs using additional markers may be of great importance, for example by improving detection of cancer stem cells. Thirdly, automated image analysis for CTC enumeration and characterisation will be highly desirable for increased throughput. Fully automated detection and analysis should be feasible for CTCscope, because false positive identification is minimal owing to the high specificity of RNAscope ISH; in contrast, IHC-based detection methods require manual morphological examination to avoid false positives. Finally, further streamlining and automation of the protocol will be needed for increased robustness for eventual clinical adoption. In conclusion, CTCscope holds great promise in detecting and characterising the heterogeneity of CTCs for both clinical research and diagnostics.
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![The CTCscope assay. (**A**) CTCscope workflow from blood sample collection to image acquisition and data analysis. (**B**) Ficoll-prepared human PBMCs spiked with MCF7, SK-BR-3, or MDA-MB-468 tumour cells were hybridised with a pooled probe set for pan-CK (*CK8*, *CK18*, and *CK19*) and *EGFR* mRNAs. Merged images are shown in the right column. Cells were counterstained with DAPI (blue). (**C**) Efficient cell recovery by the CTCscope. Low numbers of MDA-MB-468 cells were spiked into 5 ml blood, PBMCs were enriched and processed by CTCscope, and the number of cells recovered by CTCscope plotted against the number of spiked cells.](bjc2012137f1){#fig1}

![Specific identification of non-apoptotic cells by CTCscope and examples of CTCs in metastatic breast cancer patients. (**A**) MDA-MB-468 cells were hybridised with a pooled probe set for pan-CK (*CK8*, *CK18*, and *CK19*), red signal, followed by immunostaining with M30 antibody (green). (**B**) MDA-MB-468 cells were hybridised to pan-CK probes (red) followed by immunostaining with pan-CK antibody (green). Cells were counterstained with DAPI (blue). Arrows indicate apoptotic cells showing signal for CK protein but not for mRNA. (**C**) Peripheral blood mononuclear cell preparations from a metastatic breast cancer patient were hybridised with a pooled probe set for pan-CK (*CK8*, *CK18*, and *CK19*; green) and *CD45* (red) mRNAs and counterstained with DAPI. A CTC was initially identified at × 10 magnification and then confirmed by its absence of CD45 mRNA signals at × 40 magnification (insert). (**D**) Example images of patient CTCs that have similar size as PBMCs. (**E**) Example images of patient CTCs that were significantly larger than PBMCs. Both (**D**) and (**E**) at × 40. (**F**) Two CTCs (arrows) from one metastatic breast cancer patient. One of the CTCs stained strongly with panCTC mRNAs, whereas the other completely lacked any mRNA signal.](bjc2012137f2){#fig2}

![Kaplan--Meier plots of progression-free survival according to CTC status at time of sampling. Kaplan--Meier survival curves were drawn for patients with positive (dashed line) or negative (solid line) CTC status according to the cutoffs as indicated. For CA15-3, the median was used as the cutoff.](bjc2012137f3){#fig3}

######  Clinical characteristics of metastatic breast cancer patients

                                                                            **Metastatic breast cancer patients (*****n*****=45)**   **Percentage (%)**
  ------------------------------------------------------------------------- -------------------------------------------------------- --------------------
  *Age*                                                                                                                              
   Median and range                                                         60 (43--78)                                              100
                                                                                                                                      
  *Histology (primary tumour)*                                                                                                       
   Invasive ductal                                                          39                                                       87
   Invasive lobular                                                         5                                                        11
   Not known                                                                1                                                        2
                                                                                                                                      
  *Hormone receptor status (primary tumour)*                                                                                         
   ER positive                                                              37                                                       82
   ER negative                                                              8                                                        18
   PgR positive                                                             32                                                       71
   PgR negative                                                             11                                                       24
   PgR unknown                                                              2                                                        4
                                                                                                                                      
  *HER2 status (primary tumour)*                                                                                                     
   Positive                                                                 9                                                        20
   Negative                                                                 32                                                       71
   Unknown                                                                  4                                                        9
                                                                                                                                      
  *Sites of metastases at the time of sampling*                                                                                      
   Bone                                                                     25                                                       56
   Liver                                                                    19                                                       42
   Lung                                                                     13                                                       29
   Lymph nodes                                                              14                                                       31
   Other                                                                    13                                                       29
                                                                                                                                      
  *Treatment following sampling*                                                                                                     
   Aromatase inhibitor/ER antagonist                                        7                                                        16
   Chemotherapy                                                             13                                                       29
   Anti-growth factor therapy                                               2                                                        4
   Chemo/anti-growth factor receptor or bisphosphonate combination          5                                                        11
   Bisphosphonate                                                           4                                                        9
   Bisphosphonate/aromatase inhibitor combination                           8                                                        18
   Bisphosphonate/anti-growth factor receptor combination                   1                                                        2
   No treatment                                                             5                                                        11
                                                                                                                                      
  *Disease response at the following sampling*[a](#t1-fn2){ref-type="fn"}                                                            
   Partial response                                                         7                                                        16
   Stable disease                                                           15                                                       33
   Progressive disease                                                      23                                                       51
  Follow-up (months)[b](#t1-fn3){ref-type="fn"}                             16.5 (1--52)                                             100

Abbreviations: ER=oestrogen receptor; PgR=progestrone receptor.

Response criteria: as assessed by RECIST criteria ([@bib5]).

Started from the time of blood sampling for circulating tumour cell analysis.

######  Comparison of CTC detection by the CellSearch system and CTCscope in paired blood samples from 45 patients with metastatic breast cancer

                                                                                **CellSearch system**                                      **CTCscope**
  ----------------------------------------------------------------------------- ----------------------- ---------------------------------- --------------
  Patients positive for CTCs[a](#t2-fn2){ref-type="fn"} (*n*=45)                23 (51%)                                                   21 (47%)
  Patients with CTCs detected by both methods[a](#t2-fn2){ref-type="fn"}                                15 (33%)                            
  Patients with CTCs detected by either method[a](#t2-fn2){ref-type="fn"}                               16 (36%)                            
  Concordance (*P*-value)                                                                               0.017[b](#t2-fn3){ref-type="fn"}    
  Patients with CTCs detected with one method only[a](#t2-fn2){ref-type="fn"}   8 (18%)                                                    6 (13%)
  Mean no. CTCs                                                                 19.53                                                      1.56
  95% CI                                                                        6.33--32.73                                                0.4--2.71
  Median                                                                        1                                                          0
  Range                                                                         0--223                                                     0--23

Abbreviations: CI=confidence interval; CTC=circulating tumour cells.

Positive for CTCs when one or more CTCs present in 7.5 ml blood.

Statistically significant (Fisher\'s exact test).

######  Correlation of CTC detection with PFS and CA15-3

  **Univariate Cox regression**   **Correlation with CA15-3**                  
  ------------------------------- ----------------------------- ------- ------ --------
  CellSearch (CTC\>0)             2.50 (1.27--4.90)             0.008   0.52   0.0003
  CTCscope (CTC\>0)               2.26 (1.18--4.35)             0.014   0.24   0.09

Abbreviations: CI=confidence interval; CTC=circulating tumour cell; HR=hazard ratio; PFS=progression-free survival.
